Cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) compared to lamivudine as first line treatment of chronic hepatitis B (CHB) in the UK

被引：0
|
作者：
Veenstra, DL
Sullivan, SD
Dusheiko, GM
Jacobs, M
Lewis, GJ
Patel, KK
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Royal Free Hampstead NHS Trust, London, England
[3] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[4] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A120 / A120
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of peginterferon alfa-2a (40KD) compared to lamivudine for the treatment of E antigen negative chronic hepatitis B in the UK
    Veenstra, DL
    Sullivan, SD
    Lewis, G
    Green, J
    VALUE IN HEALTH, 2005, 8 (03) : 371 - 371
  • [2] Cost-effectiveness of peginterferon alfa-2a (40KD) for the treatment of chronic Hepatitis B in Italy
    Eandi, M.
    Iannazzo, S.
    Pradelli, L.
    Patel, K.
    Giuliani, G.
    VALUE IN HEALTH, 2006, 9 (06) : A301 - A302
  • [3] An evaluation of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for the first treatment of mild chronic hepatitis C (CHC)
    Hornberger, J
    Dusheiko, G
    Lewis, G
    Patel, K
    HEPATOLOGY, 2005, 42 (04) : 653A - 653A
  • [4] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [5] Cost-effectiveness of first-line peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients with mild chronic hepatitis C (cHC) in the US
    El-Serag, Hashem B.
    Patel, Kavita K.
    Wintfeld, Neil
    Green, Jesse
    Sullivan, Sean D.
    GASTROENTEROLOGY, 2006, 130 (04) : A837 - A837
  • [6] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-NEGATIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-debek, M.
    Russel-Szymczyk, M.
    VALUE IN HEALTH, 2011, 14 (07) : A277 - A277
  • [7] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-POSITIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-Debek, M.
    Russel-Szymczyk, M.
    VALUE IN HEALTH, 2011, 14 (07) : A275 - A275
  • [8] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [9] The cost effectiveness analysis of treatment with peginterferon alfa-2a (40KD) in patients with hbeag-negative chronic hepatitis B
    Kowalik, E.
    Niewada, M.
    Jakubczyk, M.
    Horban, A.
    Berak, H.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2006, 9 (06) : A300 - A300
  • [10] A comparison of cost-effectiveness of peginterferon alfa-2a (40 KD) (pegasys) plus ribavirin (copegus) versus interferon alfa-2b Plus ribavirin as first treatment of chronic hepatitis C in the UK
    Lewis, GJ
    Green, J
    Patel, K
    Philips, Z
    VALUE IN HEALTH, 2004, 7 (06) : 763 - 764
12345